- Home
- VRAR vs STTK Comparison
VRAR vs STTK Comparison
Compare VRAR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- STTK
- Stock Information
- Founded
- VRAR 2016
- STTK 2016
- Country
- VRAR United States
- STTK United States
- Employees
- VRAR N/A
- STTK N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- VRAR Technology
- STTK Health Care
- Exchange
- VRAR Nasdaq
- STTK Nasdaq
- Market Cap
- VRAR 33.3M
- STTK 37.6M
- IPO Year
- VRAR 2021
- STTK 2020
- Fundamental
- Price
- VRAR $1.59
- STTK $1.14
- Analyst Decision
- VRAR Strong Buy
- STTK Hold
- Analyst Count
- VRAR 1
- STTK 4
- Target Price
- VRAR $2.62
- STTK $3.00
- AVG Volume (30 Days)
- VRAR 190.6K
- STTK 101.1K
- Earning Date
- VRAR 05-15-2025
- STTK 07-31-2025
- Dividend Yield
- VRAR N/A
- STTK N/A
- EPS Growth
- VRAR N/A
- STTK N/A
- EPS
- VRAR N/A
- STTK N/A
- Revenue
- VRAR $8,756,789.00
- STTK $4,606,000.00
- Revenue This Year
- VRAR $6.59
- STTK N/A
- Revenue Next Year
- VRAR $30.43
- STTK N/A
- P/E Ratio
- VRAR N/A
- STTK N/A
- Revenue Growth
- VRAR N/A
- STTK 69.65
- 52 Week Low
- VRAR $0.50
- STTK $0.69
- 52 Week High
- VRAR $7.00
- STTK $7.49
- Technical
- Relative Strength Index (RSI)
- VRAR 61.35
- STTK 56.02
- Support Level
- VRAR $1.45
- STTK $0.98
- Resistance Level
- VRAR $1.76
- STTK $1.13
- Average True Range (ATR)
- VRAR 0.14
- STTK 0.10
- MACD
- VRAR 0.01
- STTK 0.01
- Stochastic Oscillator
- VRAR 66.67
- STTK 84.85
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.